ArticleBMC medicine2025

Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada.

Samara Bugden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.